Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?

Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?

Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load. Suboptimal drug concentrations may thus contribute to lack of response to therapy in patients with inf...

The Absence of Hepatitis C Virus Infection Among Patients with Hepatitis B virus in Mashhad, Iran

Background and Aims: Many studies have provided evidence for the role of hepatitis B and C viruses in the development of liver cancer. Although the routine treatment is available for both conditions, no definite guideline is available to treat patients dually infected with HBV and HCV. This study was performed to determine the frequency of HBV/HCV-coinfection in Mashhad, North-East of Iran. Mat...

CHARACTERISTICS AND PREVALENCE OF OCCULT HEPATITIS B VIRUS INFECTION IN PATIENTS WITH HEPATITIS C IN IRAN

 ABSTRACT Background: Hepatitis B virus (HBV) infection in patients who lack detectable hepatitis B surface antigen (HBsAg) is called occult hepatitis B infection. Such infections have been frequently identified in patients with chronic hepatitis Cliver disease, but their prevalence is not known. Methods: 207 patients with chronic hepatitis C who were HCV -RNA and antiHCV positive were stu...

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis

BACKGROUND An estimated 170 million people worldwide are infected with hepatitis C virus (HCV). HCV genotype 4 (HCV-4)-the most prevalent hepatitis C strain in the Middle East and Africa-is difficult to treat, with an estimated sustained virological response (SVR) of 53% when using pegylated interferon and ribavirin (P/R) in treatment-naïve patients with HCV-4 infection. In regions where access...

prevalence of hepatitis c virus infection in patients with systemic lupus erythematosus: a case-control study